Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion gradually - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Gilead Sciences stock (ISIN US3755581036) was trading at EUR 137.34 at Lang & Schwarz on October 20, 2026, 0.10 percent below the Xetra close of October 19, 2026 at EUR 137.48. On October 19, 2026, Gilead reported positive Phase 2 results for its oral emvistegrast treatment in ulcerative colitis, according to Gilead Sciences . On August 4, 2026, second-quarter total product sales reached USD 7.60 billion, up 8 percent year over year, according to the Yahoo Finance transcript. On October 15, 2026, Gilead announced that third-quarter results and guidance would be released on October 29, 2026. The company then reported the emvistegrast response data on October 19, 2026, making the inflammation pipeline the latest quantified catalyst. The trial enrolled 238 adults and tested three doses against placebo. At Week 12, the 200 mg dose produced a 66 percent clinical response rate versus 37 percent for placebo, while clinical remission reached 31 percent versus 8 percent, according to Reuters. The study remains ongoing, and Gilead plans to initiate a Phase 3 monotherapy study in 2027. The result gives Gilead an oral candidate in a validated inflammatory bowel disease pathway, but it remains an investigational program. The company said adverse events occurred in 36 percent of emvistegrast-treated participants and 37 percent of placebo participants, while the study release cautioned...
Keep reading with a free account
The rest of this article, and every signal for Gilead, is in your free account.
